PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
Community/research information onlyNo aprobado por FDA/EMAWADA

Community protocol · BPC-157

BPC-157: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: BPC 157 · Body protection compound 157

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

BPC-157

Estudiado preclínicamente para tejido gastrointestinal y reparación de heridas; beneficio y seguridad clínicos no probados.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

Calculadora de reconstitución

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Calculadora de reconstitución

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Synthetic 15-amino-acid gastric peptide fragment

BPC-157 is classified as “Synthetic 15-amino-acid gastric peptide fragment”. Estudiado preclínicamente para tejido gastrointestinal y reparación de heridas; beneficio y seguridad clínicos no probados. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Fragmento gastroprotector

Los investigadores estudian cómo un fragmento derivado de una proteína gastroprotectora afecta la curación de la mucosa gástrica y la reparación de tejidos en modelos. Se miden, entre otras cosas, el tamaño de la úlcera y la velocidad de curación en modelos animales.

02

Péptido de migración celular

Esto estudia cómo un péptido influye en la migración de las células hacia un sitio de lesión, de forma similar a los trabajadores que se apresuran a una obra. Se miden la velocidad y el alcance de la migración celular en modelos de laboratorio.

03

Modelos de reparación tisular

Los investigadores utilizan modelos controlados de heridas o lesiones en células o animales para estudiar la rapidez y la completitud con que el tejido sana tras un daño. Las medidas suelen incluir el tamaño de la herida a lo largo del tiempo y marcadores de formación de tejido nuevo, de forma similar a fotografiar un corte cada día para ver qué tan rápido cierra.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Anécdotas de cicatrización de heridas

Las personas reportan una curación percibida más rápida de lesiones o problemas de tendones tras usar ciertos péptidos, generalmente sin un grupo de control ni medición objetiva. Estos informes individuales no establecen una eficacia o seguridad reales.

Anécdotas de salud intestinal

Las personas reportan mejoras digestivas percibidas subjetivamente tras usar péptidos gastroprotectores o inmunomoduladores, generalmente sin diagnósticos objetivos. Estas autoobservaciones no establecen un efecto confirmado sobre el intestino.

Foros de recuperación y lesiones

Se comparan los tiempos de recuperación personales tras lesiones deportivas usando diferentes péptidos reparadores, a menudo basándose en escalas subjetivas de dolor. Estas evoluciones individuales están influenciadas por muchos otros factores y no prueban eficacia.

Adverse effects and risk boundaries

  • Muchos llamados péptidos reparadores carecen de estudios humanos controlados. Persisten riesgos de efectos sistémicos desconocidos, reacciones inmunes, efectos vasculares o hemorrágicos e infección/contaminación por inyección.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Embarazo, cáncer, infección activa, trastornos de coagulación, cirugía prevista y enfermedades inmunes relevantes exigen valoración especialmente estricta o evitar el uso.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No existe un esquema validado de seguimiento para péptidos reparadores no aprobados. Según el caso pueden ser relevantes exploración, inflamación, hemograma, hígado/riñón y coagulación.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclínico

La evidencia es principalmente preclínica; la eficacia en humanos no está establecida.

Published evidence

Los datos disponibles provienen principalmente de modelos animales o celulares; faltan datos sólidos de eficacia y seguridad en humanos.

BPC-157 se deriva de una proteína gastroprotectora, lo que la distingue de fragmentos relacionados con la timosina beta-4, como TB-500.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

No aprobado por FDA/EMA

No existe medicamento aprobado por FDA o EMA; eficacia y seguridad no están establecidas.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile